

Costs of current therapy (dose increase) versus therapy based on algorithm using serum IFX and ADA levels

The Danish study of Optimizing Infliximab Therapy in Crohn's disease (DO IT CROHN)
prospective, randomized, double-blind, multicenter trial, 2010-12

Economic costs in per protocol patients (US\$ per patient)

